II. Background: History
- Libby Zion was a young patient who died of Serotonin Syndrome in 1984 and set historic precedent
- Provider education regarding Serotonin Syndrome
- Principal case that limited intern and resident shift hours
- http://en.wikipedia.org/wiki/Libby_Zion_law
III. Epidemiology
- Complicates 14-16% of SSRI Overdoses
IV. Etiology
- Excessive Serotonin levels at the 5HT-2A receptor sites
- Associated with combinations of Serotoninergic drugs (e.g. SSRI, TCA, MAOI)
- Exacerbated by drugs that increase Serotonin levels (see risk factors below)
V. Risk Factors: General
- Medications with serotonergic effects (see below)
- Combined use of multiple serotonergic drugs
- Inadequate washout period between transitioning to a new serotonergic drug
- Higher Incidence with Monoamine Oxidase Inhibitors, St. John's Wort and Linezolid
- Cytochrome P450 Drug Interactions or specific patient Phenotypes
- Examples: Clarithromycin
- Increases susceptibility to Serotonin Syndrome
- Medical conditions that decrease the available monoamine oxidase
- Hypertension
- Atherosclerosis
- Hyperlipidemia
VI. Risk Factors: Serotonergic Medications
- Psychiatric medications
- Selective Serotonin Reuptake Inhibitors - SSRI (e.g. Paroxetine/Paxil or Fluoxetine/Prozac)
- Serotonin-Norepinephrine Reuptake Inhibitors - SNRI (e.g. Venlafaxine - Effexor)
- MAO Inhibitors (e.g. Phenelzine, Selegiline or Nardil)
- High risk for Serotonin Syndrome when combined with other serotinergic agents
- Tricyclic Antidepressants (e.g. Amitriptyline, Clomipramine, Imipramine)
- Lithium
- Buspar
- Trazodone
- Lower risk of Serotonin Syndrome (non-Serotonin 2A stimulation)
- Some Antipsychotic Medications (e.g. Olanzapine or Zyprexa)
- Stimulant Medications
-
Antiemetics
- Metoclopramide (Reglan)
- Ondansetron (Zofran)
- Lower risk of Serotonin Syndrome (non-Serotonin 2A stimulation)
- Droperidol (Inapsine)
-
Migraine and Seizure Medications
- Triptans (e.g. SumatriptanImitrex)
- Lower risk of Serotonin Syndrome (non-Serotonin 2A stimulation)
- Ergot Alkaloids
- Valproic Acid (Depakote, Depakene)
- Carbamazepine (Tegretol)
- Triptans (e.g. SumatriptanImitrex)
- Synthetic Opioid Analgesics
- Tramadol (Ultram)
- Higher risk for Serotonin Syndrome
- Meperidine (Demerol)
- Fentanyl (Duragesic)
- Methadone
- Dextromethorphan
- Rare case reports with Buprenorphine (Suboxone), Hydromorphone, Oxycodone or Hydrocodone
- Tramadol (Ultram)
- Muscle Relaxants
- Miscellaneous medications
- Chlorpheniramine
- Linezolid (Zyvox) - MAO Inhibitor effect
- Reserpine
- Ritonavir (Norvir)
- Locaserin (weight loss agent)
-
Herbals and supplements
- St. John's Wort
- Ginkgo Biloba
- Ginseng
- L-Tryptophan
- 5-Hydroxytryptophan (dietary supplement) - Serotonin precursor
- Yohimbine
- Recreational drugs
- Cocaine
- 3,4-methylenedioxmethamphetamine (Ecstacy)
- Methamphetamine
VII. Signs
- Mental Status Changes
- Confusion or Disorientation (51%)
- Agitation or irritability (34%)
- Somnolence, coma or unresponsiveness (29%)
- Autonomic changes
- Fever or hyperthermia (45%)
- Muscle hyperactivity and decreased heat dissipation
- Diaphoresis (45%)
- Sinus Tachycardia (36%)
- Hypertension (35%)
- Mydriasis (28%) or unreactive pupils (20%)
- Tachypnea (26%)
- Nausea (23%) or Vomiting
- Fever or hyperthermia (45%)
- Neuromuscular changes
- Myoclonic Jerks (58%)
- Hyperreflexia (52%)
- Muscle rigidity (51%)
- Restlessness or hyperactivity (48%)
- Tremor (43%)
- Ataxia or Incoordination (40%)
- Clonus (23%)
- Spontaneous Clonus with a history of Serotoninergic agent use is pathognomonic for Serotonin Syndrome
- Dunkley (2003) QJM 96 (9): 635-642 [PubMed]
- Exclude other possible causes
- Infectious, metabolic, Substance Abuse or withdrawal
- No recent Neuroleptic changes
VIII. Precautions
IX. Diagnosis: Hunter Serotonin Criteria
- Major Criteria
- Ingestion of serotinergic agent
- Other Criteria (at least one present)
- Efficacy
- Test Sensitivity: 84%
- Test Specificity: 97%
- References
X. Differential Diagnosis
- Meningitis or Encephalitis
- Anticholinergic Syndrome
- Malignant Hyperthermia
- Seizure Disorder
-
Neuroleptic Malignant Syndrome
- Occurs with Dopamine blocking agents
- Classic triad of fever, Muscle rigidity and Altered Mental Status
XI. Management
- Discontinue Serotoninergic medications
- Provide supportive care
- Treat Muscle rigidity, Tremor and hyperthermia
- First line
- Benzodiazepines decrease Agitation and adrenergic stress
- Refractory Hyperthermia (severe, critically ill patients)
- Active Cooling of Patient
- Endotracheal Intubation
- Sedation and Paralytic Agents (non-depolarizing Neuromuscular Blockers, e.g. Rocuronium)
- First line
- Consider serotonin Antagonists
- Cyproheptadine (Periactin)
- Initial protocol
- Bolus: 12 mg oral bolus dose for 1 dose (may be crushed and placed down NG or OG)
- Continued symptoms: 2 mg every 2 hours until symptoms controlled
- Expect patient sedation with Cyproheptadine dosing
- Maintenance protocol (once stabilized)
- Dose: 8 mg every 6 hours or 4 mg every 2-4 hours
- Maximum: 0.5 mg/kg/day
- Initial protocol
- Cyproheptadine (Periactin)
- Other medications that have been used for Serotonin Syndrome symptom control
- Precautions
- Avoid Antipsychotics (e.g. Haloperidol) as has serotonergic effects and may exacerbate condition
- Avoid antipyretics (ineffective)
- Hyperthermia of Serotonin Syndrome is due to increased Muscle activity (not the Hypothalamus)
XII. Course
- Many cases likely go undiagnosed and resolve spontaneously when patients stop the medications themselves
- Resolution after stopping Serotoninergic medication
- Within 24 hours in 70% of cases
- Within 96 hours in almost all cases
- High acuity care
- Intensive Care admission in up to 40% of cases
- Mechanical Ventilation in up to 25% of cases
- Rarely fatal: 11 deaths in literature
XIII. References
- Herbert and Jhun in Herbert (2015) EM:Rap 15(4):14
- Nordt and Swadron in Majoewsky (2012) EM:Rap 12(2): 3
- Otter and Tomaszewski (2018) Crit Dec Emerg Med 32(11): 28
- (2022) Presc Lett 29(9): 51-2
- Ables (2010) Am Fam Physician 81(9): 1139-42 [PubMed]
- Bodner (1995) Neurology 45:219-23 [PubMed]
- Brown (1996) Ann Pharmacother 30:529-33 [PubMed]
- Corkeron (1995) Med J Aust 163:481-2 [PubMed]
- Erner (2003) Pain Med 4(1): 63-74 [PubMed]
- Iqbal (2012) Ann Clin Psychiatry 24(4): 310-8 [PubMed]
- Kovich (2015) Am Fam Physician 92(2): 94-100 [PubMed]
- Mills (1995) Am Fam Physician 52(5):1475-82 [PubMed]